AU2010208624B2 - Compositions for radiolabeling diethylenetriaminepentaacetic acid (DTPA)-dextran - Google Patents

Compositions for radiolabeling diethylenetriaminepentaacetic acid (DTPA)-dextran Download PDF

Info

Publication number
AU2010208624B2
AU2010208624B2 AU2010208624A AU2010208624A AU2010208624B2 AU 2010208624 B2 AU2010208624 B2 AU 2010208624B2 AU 2010208624 A AU2010208624 A AU 2010208624A AU 2010208624 A AU2010208624 A AU 2010208624A AU 2010208624 B2 AU2010208624 B2 AU 2010208624B2
Authority
AU
Australia
Prior art keywords
composition
dtpa
dextran
concentration
sodium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010208624A
Other languages
English (en)
Other versions
AU2010208624A1 (en
Inventor
Gerald Ross Magneson
Richard Cushman Orahood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cardinal Health 414 LLC
Original Assignee
Cardinal Health 414 LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardinal Health 414 LLC filed Critical Cardinal Health 414 LLC
Publication of AU2010208624A1 publication Critical patent/AU2010208624A1/en
Application granted granted Critical
Publication of AU2010208624B2 publication Critical patent/AU2010208624B2/en
Assigned to NAVIDEA BIOPHARMACEUTICALS, INC. reassignment NAVIDEA BIOPHARMACEUTICALS, INC. Alteration of Name(s) of Applicant(s) under S113 Assignors: NEOPROBE CORPORATION
Assigned to CARDINAL HEALTH 414, LLC reassignment CARDINAL HEALTH 414, LLC Request for Assignment Assignors: NAVIDEA BIOPHARMACEUTICALS, INC.
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
    • A61K51/065—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules conjugates with carriers being macromolecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/005—Sugars; Derivatives thereof; Nucleosides; Nucleotides; Nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/001—Acyclic or carbocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B63/00—Purification; Separation; Stabilisation; Use of additives
    • C07B63/04—Use of additives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/534—Production of labelled immunochemicals with radioactive label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
AU2010208624A 2009-01-30 2010-01-28 Compositions for radiolabeling diethylenetriaminepentaacetic acid (DTPA)-dextran Ceased AU2010208624B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/362,778 2009-01-30
US12/362,778 US20100196272A1 (en) 2009-01-30 2009-01-30 Compositions for radiolabeling diethylenetriaminepentaacetic acid (dtpa)-dextran
PCT/US2010/000222 WO2010087959A1 (en) 2009-01-30 2010-01-28 Compositions for radiolabeling diethylenetriaminepentaacetic acid (dtpa)-dextran

Publications (2)

Publication Number Publication Date
AU2010208624A1 AU2010208624A1 (en) 2011-08-25
AU2010208624B2 true AU2010208624B2 (en) 2016-02-04

Family

ID=42395938

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010208624A Ceased AU2010208624B2 (en) 2009-01-30 2010-01-28 Compositions for radiolabeling diethylenetriaminepentaacetic acid (DTPA)-dextran

Country Status (9)

Country Link
US (4) US20100196272A1 (enExample)
EP (2) EP2392012B1 (enExample)
JP (5) JP5743905B2 (enExample)
KR (2) KR101713559B1 (enExample)
CN (1) CN102301429A (enExample)
AU (1) AU2010208624B2 (enExample)
BR (1) BRPI1007487A2 (enExample)
CA (1) CA2750230C (enExample)
WO (1) WO2010087959A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100196272A1 (en) 2009-01-30 2010-08-05 Neoprobe Corporation Compositions for radiolabeling diethylenetriaminepentaacetic acid (dtpa)-dextran
JP6163698B2 (ja) * 2013-03-21 2017-07-19 国立大学法人 千葉大学 マクロファージマンノース受容体を認識する新規多糖金属錯体化合物、及び、その医薬組成物
HK1225623A1 (zh) 2013-07-22 2017-09-15 纳维迪亚生物制药有限公司 用於诊断和治疗与表达cd206的细胞相关的病症的组合物、方法和药盒
US10328149B2 (en) 2014-06-13 2019-06-25 Tenboron Oy Conjugates comprising an anti-EGFR1 antibody
JP6722663B2 (ja) * 2014-07-17 2020-07-15 オハイオ ステート イノベーション ファウンデーション マクロファージおよび他のマンノース結合ｃ型レクチン受容体高発現細胞を標的化するための化合物および組成物、ならびにそれらを使用して治療するおよび診断する方法
US10806803B2 (en) 2014-07-17 2020-10-20 Ohio State Innovation Foundation Compositions for targeting macrophages and other CD206 high expressing cells and methods of treating and diagnosis
EP3744708B1 (en) * 2014-11-13 2023-08-09 Waters Technologies Corporation Calibrant for liquid chromatography calibration of labeled n-glycans
GB201504064D0 (en) 2015-03-10 2015-04-22 Accretion Biotechnology Ltd Method and kits for preparing radionuclide complexes
CN106317237B (zh) * 2015-07-03 2019-07-19 华中科技大学 一种用于spect成像的当归多糖衍生物及其合成方法
CN106188226B (zh) * 2016-07-04 2019-12-24 江苏省原子医学研究所 一种用于淋巴结检查的大分子显像剂及其制备方法
FR3054445B1 (fr) * 2016-07-26 2019-07-05 Laboratoires Cyclopharma Synthese d'une composition d'agent radioactif
US10695450B2 (en) 2016-07-26 2020-06-30 Laboratoires Cyclopharma Synthesis of a radioactive agent composition
US11007272B1 (en) 2016-10-07 2021-05-18 Navidea Biopharmaceuticals, Inc. Compounds and methods for diagnosis and treatment of viral infections
JP6329302B2 (ja) * 2017-05-10 2018-05-23 国立大学法人千葉大学 マクロファージマンノース受容体を認識する新規多糖金属錯体化合物、及び、その医薬組成物
JP7576334B2 (ja) * 2019-03-29 2024-10-31 国立研究開発法人量子科学技術研究開発機構 放射性医薬の製造方法及び放射性医薬
JP2023533405A (ja) 2020-07-08 2023-08-03 ナビディア、バイオファーマスーティカルズ、インコーポレイテッド 均一に定められた分子量のマンノシル化デキストランおよびその誘導体の合成
EP4525882A1 (en) 2022-05-20 2025-03-26 Navidea Biopharmaceuticals, Inc. Cd206 targeted drug delivery vehicles carrying novel bisphosphonate drug payloads via a degradable linker
US12404349B2 (en) 2022-10-03 2025-09-02 Navidea Biopharmaceuticals, Inc. Amide linkages of sugar moieties to amine terminated leashes attached to carbohydrate polymers

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4364920A (en) * 1975-04-30 1982-12-21 Medi-Physics, Inc. Stable diagnostic reagents
US6066309A (en) * 1996-02-02 2000-05-23 Rhomed Incorporated Post-labeling stabilization of radiolabeled proteins and peptides
US6409990B1 (en) * 1999-05-14 2002-06-25 The Regents Of The University Of California Macromolecular carrier for drug and diagnostic agent delivery
US7217796B2 (en) * 2002-05-24 2007-05-15 Schering Corporation Neutralizing human anti-IGFR antibody

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1053508B (it) * 1970-07-06 1981-10-10 Searle & Co Procedimento per prepare composizioni marcate adatte a mettere in evidenza alterazioni della mucosa gastrointestinale prodotto ottenuto e relativo metodo di impiego
US4048296A (en) * 1975-05-27 1977-09-13 Mallinckrodt, Inc. Radiopharmaceutical scanning agents
JPS5569517A (en) * 1978-11-20 1980-05-26 Nippon Mejifuijitsukusu Kk Labelling preparation for labelling of erythrocytes with radio-active technetium
SE465907B (sv) 1984-11-01 1991-11-18 Nyegaard & Co As Diagnosticeringsmedel innehaallande en paramagnetisk metall
US5336762A (en) 1985-11-18 1994-08-09 Access Pharmaceuticals, Inc. Polychelating agents for image and spectral enhancement (and spectral shift)
US4822594A (en) 1987-01-27 1989-04-18 Gibby Wendell A Contrast enhancing agents for magnetic resonance images
CS263561B1 (en) 1987-09-18 1989-04-14 Kery Vladimir Process for preparing water soluble allylderivatives of oligo and polysaccharides
GB8801646D0 (en) * 1988-01-26 1988-02-24 Nycomed As Chemical compounds
US5328679A (en) * 1988-04-01 1994-07-12 Immunomedics, Inc. Methods for technetium/rhenium labeling of proteins
DD286598A5 (de) 1989-06-29 1991-01-31 Adw Der Ddr,Zi F. Mulekularbiologie,De Verfahren zur einfuehrung von primaeren aminogruppen in wasserloesliche polymere
EP0516873A1 (en) * 1991-06-06 1992-12-09 THE STATE of ISRAEL Atomic Energy Commission Soreq Nuclear Research Center A method and kit for protein labelling with 99 mTC
US5789578A (en) 1996-01-11 1998-08-04 Massey University Methods for the preparation of resins with ligands attached thereto through a linking group comprising sulfide, sulfoxide or sulfone functionality
CA2279349C (en) * 1996-02-02 2007-09-25 Rhomed Incorporated Ascorbate-stabilized radiopharmaceutical method and composition
US20010055563A1 (en) * 1999-09-09 2001-12-27 Rhomed Incorporated Post-labeling stabilization of radiolabeled proteins and peptides
AU5135698A (en) 1996-11-28 1998-06-22 Nihon Schering K.K. Contrast compound, contrast medium for mri, and method for mri
US6887462B2 (en) * 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
US7666979B2 (en) 2002-03-01 2010-02-23 Bracco International B.V. Methods for preparing multivalent constructs for therapeutic and diagnostic applications and methods of preparing the same
ES2396368T3 (es) 2003-03-03 2013-02-21 Dyax Corporation Péptidos que se unen específicamente al receptor del HGF (CMET) y usos de los mismos
DK1658848T3 (da) * 2004-10-29 2007-11-26 Pharma Mar Sa Formuleringer omfattende ecteinascidin og et disaccharid
TWI398272B (zh) * 2005-03-08 2013-06-11 Intervet Int Bv 化學定義的安定劑
RU2008117396A (ru) * 2005-10-04 2009-11-10 Альк-Абелло А/С (Dk) Твердая вакцинная композиция
AU2007234612B2 (en) * 2006-12-14 2013-06-27 Johnson & Johnson Regenerative Therapeutics, Llc Protein stabilization formulations
BRPI0808259A2 (pt) * 2007-03-05 2014-07-08 Cadila Healthcare Ltd "formulação, processo de liofilização, formulação liofilizada, e processo para preparar uma formulação liofilizada"
US20100196272A1 (en) 2009-01-30 2010-08-05 Neoprobe Corporation Compositions for radiolabeling diethylenetriaminepentaacetic acid (dtpa)-dextran
HK1225623A1 (zh) 2013-07-22 2017-09-15 纳维迪亚生物制药有限公司 用於诊断和治疗与表达cd206的细胞相关的病症的组合物、方法和药盒
EP3169336A4 (en) 2014-07-17 2018-04-04 Ohio State Innovation Foundation Compositions for targeting macrophages and other cd206 high expressing cells and methods of treating and diagnosis
JP6722663B2 (ja) 2014-07-17 2020-07-15 オハイオ ステート イノベーション ファウンデーション マクロファージおよび他のマンノース結合ｃ型レクチン受容体高発現細胞を標的化するための化合物および組成物、ならびにそれらを使用して治療するおよび診断する方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4364920A (en) * 1975-04-30 1982-12-21 Medi-Physics, Inc. Stable diagnostic reagents
US6066309A (en) * 1996-02-02 2000-05-23 Rhomed Incorporated Post-labeling stabilization of radiolabeled proteins and peptides
US6409990B1 (en) * 1999-05-14 2002-06-25 The Regents Of The University Of California Macromolecular carrier for drug and diagnostic agent delivery
US7217796B2 (en) * 2002-05-24 2007-05-15 Schering Corporation Neutralizing human anti-IGFR antibody

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ANNE M WALLACE ET AL: "Lymphoseek: A Molecular Imaging Agent for Melanoma Sentinel Lymph Node Mapping", ANNALS OF SURGICAL ONCOLOGY, 2007, vol . 14, no. 2, pages 913-921 *
ANNE M WALLACE ET AL: "Lymphoseek: A Molecular Radiopharmaceutical for Sentinel Node Detection", ANNALS OF SURGICAL ONCOLOGY, vol. 10, no. 5, 2003, pages 531-538 *
DE PAULIS T: " Drug evaluation: Lymphoseek- Neoprobe's sentinel lymph node imaging agent for use in cancer patients", CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2006, vol .7 no.12, pages 1100-1107 *
ELLNER S J ET AL: "Dose-dependent biodistribution of [99mTc] DTPA-mannosyl-dextran for breast cancer sentinel lymph node mapping", NUCLEAR MEDICINE AND BIOLOGY, 2003, vol .30, pages 805-810 *
HOH C K ET AL: "Preclinical studies of [99mTc]DTPA-mannosyl-dextran*", NUCLEAR MEDICINE AND BIOLOGY, vol. 30, 2003, pages 457-464 *
HOH C K ET AL: "Preclinical studies of 99mTc-DTPA-mannosyl-dextran", JOURNAL OF NUCLEAR MEDICINE; Proceedings of the SNM 49t Annual Meeting; Poster sessions, vol. 43, no. 5 Supplement, 1469, page 365P *
MENDEZ J ET AL: "Detection of gastric and colonic sentinel nodes through endoscopic administration of Tc-DTPA-mannosyl-dextran in pigs", JOURNAL OF NUCLEAR MEDICINE, 2003, vol. 44, pages 1677-1681 *
VERA DAVID R ET AL: "A synthetic macromolecule for sentinel node detection: 99mTc-DTPA-mannosyl-dextran", JOURNAL OF NUCLEAR MEDICINE, 2001, vol. 42, pages 951-959 *

Also Published As

Publication number Publication date
KR20110115148A (ko) 2011-10-20
EP2392012B1 (en) 2021-01-20
JP6833892B2 (ja) 2021-02-24
EP2392012A4 (en) 2012-11-14
KR20170027874A (ko) 2017-03-10
US20100196272A1 (en) 2010-08-05
CN102301429A (zh) 2011-12-28
JP2021088566A (ja) 2021-06-10
US20160347679A1 (en) 2016-12-01
US8545808B2 (en) 2013-10-01
BRPI1007487A2 (pt) 2018-02-20
JP2019178133A (ja) 2019-10-17
JP6040276B2 (ja) 2016-12-07
CA2750230C (en) 2018-06-05
JP6509796B2 (ja) 2019-05-08
JP2012516328A (ja) 2012-07-19
JP2017066148A (ja) 2017-04-06
JP5743905B2 (ja) 2015-07-01
CA2750230A1 (en) 2010-08-05
EP2392012A1 (en) 2011-12-07
WO2010087959A1 (en) 2010-08-05
KR101713559B1 (ko) 2017-03-08
EP3884965A1 (en) 2021-09-29
JP2015164933A (ja) 2015-09-17
US20120213700A1 (en) 2012-08-23
AU2010208624A1 (en) 2011-08-25
US9439985B2 (en) 2016-09-13
KR101765717B1 (ko) 2017-08-07
US20140023586A1 (en) 2014-01-23

Similar Documents

Publication Publication Date Title
AU2010208624B2 (en) Compositions for radiolabeling diethylenetriaminepentaacetic acid (DTPA)-dextran
Peters The utility of [99mTc] HMPAO-leukocytes for imaging infection
ES2906332T3 (es) 99MTc-EDDA/HYNIC-iPSMA como un radiofármaco para detectar la sobreexpresión de antígeno prostático específico de membrana
PL204239B1 (pl) Sposób znakowania promieniotwórczego proteiny lub peptydu za pomoca itru-90
Callahan et al. Preclinical evaluation and phase I clinical trial of a 99mTc-labeled synthetic polymer used in blood pool imaging.
Monteiro et al. Technetium-99 m radiolabeled paclitaxel as an imaging probe for breast cancer in vivo
Kumar Radiolabeled white blood cells and direct targeting of micro-organisms for infection imaging
US10363324B2 (en) Pharmaceutical composition
SA08290417B1 (ar) تركيبة دوائية ثابتة تشمل ملح فينفلونين القابل للذوبان فى الماء
Avc𝚤baş𝚤 et al. Radiolabeling of new generation magnetic poly (HEMA–MAPA) nanoparticles with 131I and preliminary investigation of its radiopharmaceutical potential using albino Wistar rats
US20250127941A1 (en) Detection and localization of internal bleeding
Zeglis et al. Radiopharmaceuticals for imaging in oncology with special emphasis on positron-emitting agents
Núñez et al. Combining dose and injection volume for good performance of a specific radiopharmaceutical for sentinel node detection
Laverman et al. Radiolabeling of liposomes for scintigraphic imaging
Faintuch et al. Lanreotide and octreotide complexed with technetium-99m: labeling, stability and biodistribution studies
Gregory Radiolabeling of Liposomes for Scintigraphic Imaging
Peter Laverman et al. 2 A novel method to label liposomes with Tc-99m by the hydrazino nicotinyl derivative

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: CARDINAL HEALTH 414, LLC

Free format text: FORMER OWNER(S): NAVIDEA BIOPHARMACEUTICALS, INC.

MK14 Patent ceased section 143(a) (annual fees not paid) or expired